tirofiban has been researched along with Coronary Artery Disease in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 26 (72.22) | 29.6817 |
| 2010's | 8 (22.22) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Liu, C; Wang, J; Wang, S; Xue, Y | 1 |
| Dager, WE; Walker, EA | 1 |
| Fracassi, F; Jang, IK; Lee, H; Sugiyama, T; Xing, L; Yamamoto, E; Yu, B | 1 |
| Grove, MM; Jessup, DB; Kirby, A; Marks, S | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Ding, FH; Du, R; Hu, J; Liao, ML; Shen, WF; Wang, XL; Yang, ZK; Zhang, JS; Zhang, Q; Zhang, RY; Zhu, TQ | 1 |
| Juergens, CP; Winter, JP | 1 |
| Giannitsis, E; Ivandic, BT; Katus, HA; Keck, F; Kurz, K; Lehrke, S; Staritz, P | 1 |
| Cavusoglu, E; Lazar, J; Marmur, JD; Poludasu, S | 1 |
| Zijlstra, F | 1 |
| Andreotti, F; Brancati, M; Burzotta, F; Crea, F; De Vita, M; Giammarinaro, M; Leone, AM; Mazzari, MA; Niccoli, G; Porto, I; Schiavoni, G; Talarico, GP; Todaro, D; Trani, C | 1 |
| Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P | 1 |
| Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G | 1 |
| Bongo, AS; Cavallino, C; Lazzero, M; Lupi, A; Rognoni, A; Sansa, M; Secco, GG | 1 |
| Steinhubl, SR | 1 |
| Berger, A; Freeman, A | 1 |
| Jacobs, C; Kelm, M; Meila, D; Scharf, RE; Schrör, K; Strauer, BE; Weber, AA; Weber, S; Zotz, RB | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Amikam, S; Gruberg, L | 1 |
| Casserly, IP; Chew, DP; Cohen, DJ; DiBattiste, PM; Hamm, C; Jia, G; Lakkis, N; Lange, RA; Meier, B; Moliterno, DJ; Stone, GW; Topol, EJ | 1 |
| Heitzer, T; Köke, K; Meinertz, T; Munzel, T; Ollmann, I | 1 |
| Gil, RJ; Rzezak, J | 1 |
| Aquilina, M; Branzi, A; Gaiba, W; Marrozzini, C; Marzocchi, A; Neri, S; Ortolani, P; Palmerini, T | 1 |
| Cook, SL; Garza, L; Jacoski, MV; Jennings, LK; Matin, Z; McGrew, FA; Ramanathan, KB; Saucedo, JF; Wolford, DC | 1 |
| Goldmann, BU; Heitzer, T; Munzel, T; Nowak, G; Ostad, MA; Warnholtz, A | 1 |
| Azar, RR; Badaoui, G; Germanos, M; Kassab, R; Klaymé, S; Naman, R; Salamé, E; Sarkis, A | 1 |
| Baumann, PQ; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Akgul, O; Cam, N; Erdem, I; Kasikcioglu, H; Okmen, E; Samur, H; Simsek, D; Tartan, Z; Unal Dayi, S; Uyarel, H; Uzunlar, B | 1 |
| Dorsch, MP; Montague, D; Patterson, C; Rodgers, JE | 1 |
| Ligon, RW; Markwell, SJ; Mishkel, GJ; Moore, AL | 1 |
| Anderson, JL; Bair, TL; Burke, JL; Casterella, PJ; Horne, B; May, HT; Muhlestein, JB; Pearson, RR; Revenaugh, JR | 1 |
| Sax, FL; Snapinn, SM; Théroux, P; Zhao, XQ | 1 |
| Caputo, RP; Esente, P; Giambartolomei, A; Reger, M; Simons, A; Wagner, S | 1 |
| Davie, AP; McMurray, JJ | 1 |
| Bertrand, M; Cohen, DJ; Cohen, EA; Cohen, M; DiBattiste, PM; Grines, CL; Herrmann, HC; Moliterno, DJ; Moses, JW; Neumann, FJ; Powers, ER; Stone, GW; Topol, EJ; Wolski, K | 1 |
| DiBattiste, PM; Jang, IK; Januzzi, JL; Snapinn, SM; Theroux, P | 1 |
2 review(s) available for tirofiban and Coronary Artery Disease
| Article | Year |
|---|---|
The role of tirofiban in the management of coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Cost-Benefit Analysis; Drug Design; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2008 |
Update on glycoprotein IIb/IIIa: role in primary coronary intervention.
Topics: Abciximab; Angioplasty; Animals; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Disease; Coronary Vessels; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2011 |
14 trial(s) available for tirofiban and Coronary Artery Disease
| Article | Year |
|---|---|
Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Topics: Aged; Biomarkers; Chi-Square Distribution; China; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Creatine Kinase, MB Form; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Prosthesis Design; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Up-Regulation | 2015 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Necrosis; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Diabetes Complications; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardium; Necrosis; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Resistance; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
Topics: Acute Disease; Aged; Angina Pectoris; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Fees, Pharmaceutical; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Smoking; Statistics as Topic; Stroke Volume; Survival Analysis; Syndrome; Tirofiban; Tyrosine | 2002 |
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Coagulation; Blood Coagulation Tests; Clinical Trials as Topic; Coronary Artery Disease; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Time Factors; Tirofiban; Tyrosine | 2003 |
Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
Topics: Acetylcholine; Biological Availability; Blood Flow Velocity; Blood Platelets; Coronary Artery Disease; Endothelium, Vascular; Enzyme Inhibitors; Eptifibatide; Forearm; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Donors; omega-N-Methylarginine; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Plethysmography; Tirofiban; Tyrosine; Vasodilation; Vasodilator Agents; Vasomotor System | 2003 |
Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Topics: Angioplasty, Balloon, Coronary; Arkansas; Coronary Artery Disease; Eptifibatide; Female; Humans; Infusions, Intravenous; Male; Mississippi; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tennessee; Tirofiban; Tyrosine; United States | 2004 |
Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.
Topics: Aged; Brachial Artery; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; C-Reactive Protein; CD40 Ligand; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome managemen
Topics: Aged; Angina, Unstable; Anticoagulants; Arteriosclerosis; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Thrombosis; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Coronary Artery Disease; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Severity of Illness Index; Stents; Thrombocytopenia; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS
Topics: Acute Disease; Aged; Coronary Artery Disease; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Assessment; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
20 other study(ies) available for tirofiban and Coronary Artery Disease
| Article | Year |
|---|---|
Safety and Efficacy of Tirofiban Bridging Therapy During a Hybrid Carotid Artery Stenting and Off-pump Coronary Artery Bypass Grafting Surgery: A Single-center Study.
Topics: Carotid Arteries; Carotid Stenosis; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Stroke; Tirofiban; Treatment Outcome | 2023 |
Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single-Center Case Series Analysis Including Patients on Hemodialysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Intraoperative Care; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Renal Dialysis; Retrospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Thrombus resolution with tirofiban in the conservative management of patients presenting with plaque erosion.
Topics: Acute Coronary Syndrome; Adult; Aged; Cardiac Catheterization; Conservative Treatment; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tirofiban; Tomography, Optical Coherence | 2018 |
Planned use of GP IIb/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold.
Topics: Abciximab; Absorbable Implants; Aged, 80 and over; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Retrospective Studies; Tirofiban; Tissue Scaffolds; Treatment Outcome | 2018 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The illusion of "optimal" platelet inhibition.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Blood Platelets; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Tirofiban; Tyrosine | 2012 |
Imaging of left main coronary artery thrombus with CT coronary angiography.
Topics: Acute Coronary Syndrome; Anticoagulants; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Echocardiography; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2012 |
Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Antigens, Human Platelet; Case-Control Studies; Coronary Artery Disease; Eptifibatide; Female; Genotype; Humans; Immunoglobulin Fab Fragments; Incidence; Integrin beta3; Male; Middle Aged; P-Selectin; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Tirofiban; Tyrosine | 2002 |
Prolonged systemic delivery of tirofiban in a thrombus-laden saphenous vein graft.
Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Infusions, Intravenous; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Radiography; Saphenous Vein; Thromboembolism; Tirofiban; Tyrosine | 2003 |
[Angiogram of the month].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Fibrinolytic Agents; Humans; Male; Middle Aged; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Phosphorus Radioisotopes; Reoperation; Saphenous Vein; Stents; Ticlopidine; Tirofiban; Tyrosine | 2003 |
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Topics: Adenosine Diphosphate; Aged; Binding, Competitive; Blood Platelets; Clopidogrel; Coronary Artery Disease; Data Interpretation, Statistical; Eptifibatide; Fibrinogen; Flow Cytometry; Fluorescein-5-isothiocyanate; Humans; Iodine Radioisotopes; Male; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.
Topics: Adult; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Echocardiography; Electrocardiography; Female; Fibrinolytic Agents; Heart Conduction System; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Reproducibility of Results; Research Design; Retrospective Studies; Stents; Stroke Volume; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2006 |
Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Coronary Artery Disease; Costs and Cost Analysis; Drug Delivery Systems; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Length of Stay; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Artery Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Tirofiban; Tyrosine | 2008 |
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Topics: Aged; Aged, 80 and over; Anticoagulants; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Insufficiency; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for?
Topics: Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Europe; Fibrinolytic Agents; Health Care Costs; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |